Janney Montgomery Scott initiated coverage on shares of PLx Pharma (NASDAQ:PLXP) in a research report released on Friday, Briefing.com Automated Import reports. The firm issued a buy rating on the biotechnology company’s stock.
A number of other research firms also recently issued reports on PLXP. ValuEngine upgraded shares of PLx Pharma from a sell rating to a hold rating in a report on Friday, March 15th. JMP Securities assumed coverage on shares of PLx Pharma in a report on Thursday, March 14th. They issued an outperform rating on the stock. Raymond James downgraded shares of PLx Pharma from an outperform rating to a market perform rating in a report on Monday, January 14th. Finally, Zacks Investment Research downgraded shares of PLx Pharma from a hold rating to a sell rating in a report on Wednesday, January 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $4.75.
NASDAQ PLXP opened at $5.40 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.14 and a current ratio of 3.14. PLx Pharma has a 12-month low of $1.00 and a 12-month high of $6.44. The company has a market capitalization of $47.25 million, a PE ratio of -4.00 and a beta of 5.33.
PLx Pharma (NASDAQ:PLXP) last posted its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.06. PLx Pharma had a net margin of 1.09% and a negative return on equity of 186.01%. The company had revenue of $0.29 million for the quarter. On average, analysts predict that PLx Pharma will post -1.15 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Park West Asset Management LLC increased its holdings in PLx Pharma by 37.0% during the fourth quarter. Park West Asset Management LLC now owns 1,473,218 shares of the biotechnology company’s stock worth $2,254,000 after buying an additional 397,495 shares during the last quarter. Vanguard Group Inc. increased its holdings in PLx Pharma by 98.0% during the third quarter. Vanguard Group Inc. now owns 163,431 shares of the biotechnology company’s stock worth $662,000 after buying an additional 80,910 shares during the last quarter. Finally, Vanguard Group Inc increased its holdings in PLx Pharma by 98.0% during the third quarter. Vanguard Group Inc now owns 163,431 shares of the biotechnology company’s stock worth $662,000 after buying an additional 80,910 shares during the last quarter. Institutional investors and hedge funds own 24.24% of the company’s stock.
PLx Pharma Company Profile
PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.
Recommended Story: What does relative strength index mean?
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.